Logo

Bayer's Verquvo (vericiguat) Receives MHLW's Approval for Chronic Heart Failure

Share this

Bayer's Verquvo (vericiguat) Receives MHLW's Approval for Chronic Heart Failure

Shots:

  • The approval is based on the P-III VICTORIA trial involves assessing Verquvo (2.5mg- 5mg & 10mg) in patients with CHF- published in NEJM in Mar’20. The therapy is being jointly developed with MSD
  • The therapy has been studied specifically for patients who have experienced recent worsening HF events to reduce the risk of further worsening events. Additionally- therapy has been submitted for marketing authorization in China along with multiple other countries globally
  • Vericiguat is the 1st sGC stimulator- received the US FDA’s approval in Jan’21 and CHMP has recommended for marketing authorization in EU in May’21

  | Ref: Bayer | Image: The Business Journals

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions